









Markets
/
Stocks
/
nasdaq-fulc
/

Fulcrum Therapeutics Inc

FULC

9.740USD

+0.190+1.99%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

527.02MMarket Cap

LossP/E TTM



Fulcrum Therapeutics Inc

9.740

+0.190+1.99%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Fulcrum Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Fulcrum Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 61 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fulcrum Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

61 / 392

Overall Ranking

180 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Fulcrum Therapeutics Inc Highlights

StrengthsRisks

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1161.43% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 80.00M.

Fairly Valued

The company’s latest PE is -8.55, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 248.20K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.35.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

19.000

Target Price

+98.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Fulcrum Therapeutics Inc is 7.26, ranking 132 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.26

Change



Financials

2.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.28

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.22

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Fulcrum Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Fulcrum Therapeutics Inc is 6.75, ranking 228 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.55, which is -88.09% below the recent high of -1.02 and -14357.75% above the recent low of -1236.18.

Score

Industry at a Glance

Previous score

6.75

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 61/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Fulcrum Therapeutics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 25.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

19.000

Target Price

+91.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Fulcrum Therapeutics Inc

FULC

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Fulcrum Therapeutics Inc is 7.14, ranking 99 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.99 and the support level at 8.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.00

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.176

Sell

RSI(14)

40.705

Neutral

STOCH(KDJ)(9,3,3)

13.381

Oversold

ATR(14)

0.711

Low Volatility

CCI(14)

-167.066

Sell

Williams %R

87.290

Oversold

TRIX(12,20)

-0.248

Sell

StochRSI(14)

22.325

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

10.080

Sell

MA10

10.440

Sell

MA20

10.386

Sell

MA50

11.016

Sell

MA100

9.987

Sell

MA200

8.309

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Fulcrum Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 143.06%, representing a quarter-over-quarter decrease of 1.03%. The largest institutional shareholder is The Vanguard, holding a total of 3.56M shares, representing 5.40% of shares outstanding, with 9.56% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

6.05M

-40.82%

Suvretta Capital Management, LLC

5.38M

+5.86%

TCG Crossover Management, LLC

5.25M

Nantahala Capital Management, LLC

4.67M

+8.92%

The Vanguard Group, Inc.

Star Investors

3.00M

-4.67%

BlackRock Institutional Trust Company, N.A.

3.16M

-15.07%

Adage Capital Management, L.P.

2.43M

-47.00%

Balyasny Asset Management LP

1.45M

+8.39%

D. E. Shaw & Co., L.P.

1.45M

+23.18%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fulcrum Therapeutics Inc is 2.65, ranking 214 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 3.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.